AI
Monday, December 12, 2005 11:03:56 PM
XNPT
Closed up almost 15% on 4.5 times average daily volume, and in after hours trading gained another 9%. No news.
The only explanation I can come up with is that the market is revaluing the company on the basis of the Astellas deal.
Given that the deal includes a total of $85 million in upfront and milestone payments for Japan and five other Asian countries, and that Astellas has to take XP1352 all the way from phase I, how much are the US and European rights worth in light of relative market size and the fact that the drug is in P3?
With my luck, I'll give back most of today's gain over the next few weeks...nevertheless, I'm curious about what is going on (if anything).
Now I will stop talking about XNPT, since there appears to be no interest.
J
Closed up almost 15% on 4.5 times average daily volume, and in after hours trading gained another 9%. No news.
The only explanation I can come up with is that the market is revaluing the company on the basis of the Astellas deal.
Given that the deal includes a total of $85 million in upfront and milestone payments for Japan and five other Asian countries, and that Astellas has to take XP1352 all the way from phase I, how much are the US and European rights worth in light of relative market size and the fact that the drug is in P3?
With my luck, I'll give back most of today's gain over the next few weeks...nevertheless, I'm curious about what is going on (if anything).
Now I will stop talking about XNPT, since there appears to be no interest.
J
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
